The successful vaccine trials for honeybees, together with recent breakthrough results from clinical trials for disease prevention in shrimp, further...
WAKEFIELD, Mass., Nov. 4, 2025 /PRNewswire/ -- Odyssey, a leading provider of integrated defense capabilities and technologies, announced today it...
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual...
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech...
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has...
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and...
Dr. Jay Greenstein, CEO of Embody Health, joins the Disruption/Interruption podcast to discuss how fusing AI with behavioral science and...
New multi-modal GenAI solution accelerates report authoring and introduces breakthrough "Figures-to-Text" interpretation for faster, context-aware clinical insights CAMPBELL, Calif., Oct....
Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross...
Collaboration will leverage the exchange of expertise, develop innovative supply-chain models, and assess technology-driven solutions to improve product availability Strategic...
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000...
COPENHAGEN, Denmark, October 29, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby...
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- ObvioHealth, a global leader in digital clinical trial solutions, announced that it has signed...
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for...
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting...
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of...
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net...
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in...
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live...